Recruiting studies: Egfr Overexpression

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic H
Phase 1 · 91 location(s) · AstraZeneca · NCT04686305 Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
Phase 1/Phase 2 · 1 location(s) · Northwell Health · NCT02861898 A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel
Phase 3 · 317 location(s) · AbbVie · NCT04928846 Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
Phase 2 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT07323641 Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Phase 1/Phase 2 · 4 location(s) · Yuhan Corporation · NCT06975410 HER-2 B Cell Peptide Vaccine
Phase 1 · 1 location(s) · Pravin T.P Kaumaya · NCT06414733 Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive
Phase 2 · 1 location(s) · Tianjin Medical University Second Hospital · NCT07712029 Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Phase 1/Phase 2 · 42 location(s) · ORIC Pharmaceuticals · NCT05315700 Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
Phase 3 · 1 location(s) · Sunshine Lake Pharma Co., Ltd. · NCT04415853 Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression
Phase 1/Phase 2 · 1 location(s) · The First Affiliated Hospital of Guangzhou Medical Universit · NCT05777278 Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
Phase 1/Phase 2 · 1 location(s) · Avistone Biotechnology Co., Ltd. · NCT06343064 A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doubl
Phase 3 · 1 location(s) · Shanghai JMT-Bio Inc. · NCT06829459

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.